Prof John G Gribben

MD DSc FMedSci

Professor and Consultant Haematologist

Professor Gribben specialises in haematological cancers including lymphomas, leukaemias and bone marrow transplantation.

Headshot of The London Clinic consultant, Prof John G Gribben

Specialist interest

Haematology, Oncology

Languages

English

Available for

In-person, Video call

Prof John G Gribben Consultant Profile

Professor John Gribben, MD, DSc, FMedSci currently leads the Centre for Haemato-Oncology at Barts Cancer Institute at Queen Mary, University of London, UK, where he holds the Gordon Hamilton Fairley Chair of Medical Oncology. He is an honorary consultant in haemato-oncology and has served as director of the Stem Cell Transplantation and Immune Effector Cell Program at St Bartholomew’s Hospital, Barts Health NHS Trust for the past 20 years.

He completed his doctoral studies at University College London and at Harvard Medical School and continued his postdoctoral training in medical oncology and then joined the Faculty at the Dana-Farber Cancer, Harvard Medical School, Boston Massachusetts, USA.

He is an author of more than 575 articles and chapters in peer-reviewed publications. He was a founding member of the CLL Research Consortium and was awarded the Binet-Rai medal for CLL research from iwCLL in 2017. He served as an Editor of Blood from 2007 to 2014. He is a Fellow of the Royal College of Physicians, and the Royal College of Pathologists. He was elected as a member of the American Society for Clinical Investigation and a Fellow of the Academy of Medical Science. He is Chair of the international workshop on non-Hodgkin’s Lymphoma (iwNHL) and also served as chair of the international workshop for CAR-T cells (iwCART). He was President of the European Hematology Association from 2019-2021. He was awarded the prestigious Jose Carreras Career Development Medal acknowledging his lifetime contributions to research in haematologic malaignancies in 2024.

More Information

CART-cell therapy

Middle East Medical Portal

03/09/2019

Professor John G Gribben explains why CART-cell therapy has the potential to revolutionise cancer treatment.

Q&A: Professor John Gribben

Marylebone Journal

05/08/2019

Consultant haematologist at The London Clinic on CAR T cell therapy, which has the potential to revolutionise cancer treatment.

How 53-year-old retail worker became one of the first NHS patients to be saved by ‘miracle’ cancer treatment

Professor Gribben is quoted in this Daily Mail news report on a pioneering immunotherapy treatment.

Q&A: Prof John Gribben

Marylebone Journal

Professor Gribben’s interview with the Marylebone Journal sees him talk stem cells, research and the immune system.

Professor John G Gribben is available through The London Clinic’s Connect service for video consultations.

Book a video call now

  • Hamilton Fairley Professor of Medical Oncology Centre Lead Centre for Haemato-Oncology Barts Cancer Institute Barts and The London School of Medicine and Dentistry Queen Mary University of London
  • Consultant Haemato-Oncologist, Director, Stem Cell Transplantation and Immune Cellular Therapy Saint Bartholomew’s Hospital, London UK
  • Past President European Hematology Association
  • University of Glasgow
  • University College London
  • Harvard Medical School

Call or email the consultant’s secretary Kim Bergmann.

Send an email

02031318072